Drug Trial Radar · NCT01694771
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
Last checked: Nov 19, 2026Latest source record: Sep 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,134
Actual
Start
Sep 2012
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
TiotropiumDrug
Marketed dose
Placebo matching OlodaterolDrug
One dose
OlodaterolDrug
One dose
TiotropiumDrug
Marketed dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks
- Trough FEV1 Response at 12 Weeks; Defined as Change From Baseline to Week 12Time frame: baseline and 12 weeks
Locations
90 sites in 1 country. Site status is shown where the registry gives one.
1222.51.01055 Boehringer Ingelheim Investigational Site
Florence, Alabama
1222.51.01087 Boehringer Ingelheim Investigational Site
Jasper, Alabama
1222.51.01066 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1222.51.01069 Boehringer Ingelheim Investigational Site
Scottsdale, Arizona
1222.51.01040 Boehringer Ingelheim Investigational Site
Anaheim, California
1222.51.01064 Boehringer Ingelheim Investigational Site
Encinitas, California
1222.51.01060 Boehringer Ingelheim Investigational Site
Fullerton, California
1222.51.01084 Boehringer Ingelheim Investigational Site
Lincoln, California
1222.51.01041 Boehringer Ingelheim Investigational Site
San Diego, California
1222.51.01094 Boehringer Ingelheim Investigational Site
San Diego, California
1222.51.01015 Boehringer Ingelheim Investigational Site
Torrance, California
1222.51.01052 Boehringer Ingelheim Investigational Site
Boulder, Colorado
1222.51.01010 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
1222.51.01042 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
1222.51.01070 Boehringer Ingelheim Investigational Site
Stamford, Connecticut
1222.51.01006 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1222.51.01021 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1222.51.01082 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1222.51.01065 Boehringer Ingelheim Investigational Site
DeLand, Florida
1222.51.01051 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1222.51.01092 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1222.51.01081 Boehringer Ingelheim Investigational Site
Ormond Beach, Florida
1222.51.01054 Boehringer Ingelheim Investigational Site
Panama City, Florida
1222.51.01062 Boehringer Ingelheim Investigational Site
Pensacola, Florida
1222.51.01088 Boehringer Ingelheim Investigational Site
Port Orange, Florida
1222.51.01079 Boehringer Ingelheim Investigational Site
Tamarac, Florida
1222.51.01075 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1222.51.01076 Boehringer Ingelheim Investigational Site
Austell, Georgia
1222.51.01057 Boehringer Ingelheim Investigational Site
Duluth, Georgia
1222.51.01086 Boehringer Ingelheim Investigational Site
Lawrenceville, Georgia
1222.51.01019 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho
1222.51.01027 Boehringer Ingelheim Investigational Site
Eagle, Idaho
1222.51.01048 Boehringer Ingelheim Investigational Site
Arlingron Heights, Illinois
1222.51.01044 Boehringer Ingelheim Investigational Site
River Forest, Illinois
1222.51.01043 Boehringer Ingelheim Investigational Site
Skokie, Illinois
1222.51.01090 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
1222.51.01023 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
1222.51.01071 Boehringer Ingelheim Investigational Site
Opelousas, Louisiana
1222.51.01050 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts
1222.51.01049 Boehringer Ingelheim Investigational Site
Ann Arbor, Michigan
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.